A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis
← catalyst calendarNCT06396039 · readout in 863 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
84estimated
Sites
25
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-15 | actual | When the study began enrolling |
| Primary completion | 2028-12-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsing Multiple Sclerosis
Intervention
- Drug: BMS-986374 — also filed as Ozanimod
Primary outcome
what the primary-completion date above is the date OFAnnualized relapse rate (ARR) over 36 months
measured Up to 3 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed